This document is only valid for the day on which it is accessed. Please read our disclaimer.
This protocol provides a brief overview of cardiomyopathy giving a clinically oriented classification system in which heart muscle disorders are grouped according to ventricular morphology and function.
The protocol makes recommendations for clinical investigations and referrals for the infant / child with acute presentation with dilated, hypertropic and restrictive cardiomyopathy or acute myocarditis.
See: " Check list for acute presentation of DCM, HCM, RCM or acute myocarditis" and " Investigations for acute presentation of DCM, HCM, RCM or acute myocarditis" including first and second tier laboratory investigations.
Please note: Check lists should be used as guide and should not supersede clinical judgment
Presentation with dilated, hypertropic and restrictive cardiomyopathy warrants referral to specialist cardiologist to coordinate specific investigations and referrals to Genetic and Metabolic services as indicated.
Cardiomyopathies are a challenging group of disorders to classify, because of evolving understanding of genetic aetiology and different systems of classification. In this protocol cardiomyopathy, as defined by the Working Group of Myocardial and Pericardial Disease of the European Society of Cardiology (ESC), is: "A myocardial disorder in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality" 1,4. This is a clinically orientated classification system in which heart muscle disorders are grouped according to specific morphology and functional phenotypes; each phenotype is then sub classified into familial (genetic) and non-familial forms (Figure 1).
Taken from European Society of Cardiology classification of primary cardiomyopathies 1 (Elliot, et al., 2008). HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; RCM, restrictive cardiomyopathy; ARVC, arrhythmogenic right ventricular cardiomyopathy.
- Dilated cardiomyopathy (DCM)
- Hypertrophic cardiomyopathy (HCM)
- Restrictive cardiomyopathy (RCM)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC): an uncommon form of inherited heart disease (estimated prevalence 1:5000), involves predominately the right ventricle with progressive replacement of right ventricular myocardium with adipose and fibrous tissue. Can also occur in the left ventricle, producing a DCM phenotype. Familial disease is common with autosomal inheritance and incomplete penetrance. Presentation with arrhythmias and sudden death1,4. Not dealt with further in this document.
- Unclassified cardiomyopathies
- Left ventricular non-compaction (LVNC): is characterized by prominent left ventricular trabeculae and deep inter-trabecular recesses ("spongy" appearance of LV)1,2,. LVNC is associated with left ventricular dilatation and systolic dysfunction, which can be transient in neonates. It is not clear whether LVNC is a separate cardiomyopathy, or a congenital or acquired morphological trait shared by many phenotypically distinct cardiomyopathies1. LVNC occurs in isolation and in association with congenital cardiac disorders, complex cyanotic heart disease and some neuromuscular disorders1,2. Not dealt with further in this document.
- Takotsubo cardiomyopathy (Transient left ventricular apical ballooning syndrome): characterized by transient regional systolic dysfunction involving the left ventricular apex and/or mid-ventricle in the absence of obstructive coronary disease on coronary angiography1. Not dealt with further in this document.
NB: Many HCM / DCM / LV non compaction genes
can have overlapping phenotypes in the same family - can present at
different ages and with differing presentations - see Cardiomyopathy Tests at Partners Healthcare
Refer to Examples of different diseases that cause cardiomyopathies
Dilated Cardiomyopathy (DCM)
Dilated cardiomyopathy is defined as the presence of left ventricular dilatation and left ventricular systolic dysfunction in the absence of abnormal loading conditions (i.e. hypertension, valve disease) or coronary artery disease sufficient to cause global systolic impairment. Right ventricular dilation and dysfunction may be present but is not necessary for the diagnosis. DCM may be idiopathic, familial/genetic, viral and/or immune, alcoholic/toxic, or associated with recognized cardiovascular disease in which the degree of myocardial dysfunction is not explained by the abnormal loading conditions or the extent of ischemic damage4 i.e. post myocarditis, familial/genetic, endocrine (acquired DCM), nutritional deficiencies (acquired DCM), ischaemic, tachymyopathy and other miscellaneous causes. See Examples of different diseases that cause cardiomyopathies
DCM can occur at a late stage following cardiac infection and inflammation. In contrast to active or fulminant myocarditis, an acute inflammatory disorder of the heart, inflammatory DCM is defined by the presence of chronic inflammatory cells in association with left ventricular dilatation 1.
Histology and / or immunochemistry are needed for diagnosis.
25% of Western populations have evidence for familial disease with predominantly autosomal dominant inheritance. Familial disease should be suspected when there is a family history of premature cardiac death, conduction system disease or skeletal myopathy 1.
Pointers in examination:
Take a family history and suspect if:
- Family history of heart failure, sudden death, conduction disorders, atrial fibrillation, pacemakers, stroke (embolus from dilated cardiac chambers), muscular dystrophy in the family (problems with getting up from chair, lifting arms above head, mobility etc.
- The genetic differential diagnosis of DCM is wide and there are more than 20 gene candidates for which testing is available. Thus, genetic testing, unless via a gene panel, is not a first tier test.
- If the cause of DCM remains unexplained or there is a suspicious family history, a referral to Clinical Genetics is warranted. Screening of first degree relatives may be warranted as well as further genetic testing.
- If CK is elevated (do total CK and isoenzyme CK-MB) or the neurological exam is abnormal consider neurology consult to find cause of the combined skeletal and cardiac myopathy (eg Becker/Duchenne, Emory Dreifuss syndrome, end-stage Infantile Pompe disease).
Hypertrophic Cardiomyopathy (HCM)
Defined by the presence of increased ventricular wall thickness
or mass, in the absence of loading conditions (systemic
hypertension, valve disease i.e aortic valve stenosis) that are
sufficient to cause the observed abnormality1. The
myocardium has an enhanced contractile state, but diastolic filling
is impaired because of abnormal stiffness of the left ventricle.
This may lead to left atrial enlargement and pulmonary venous
congestion 4. The aetiology is heterogeneous, usually familial,
with autosomal dominant inheritance predominating 1,4.
'Familial HCM' is caused by a variety of mutations in genes
encoding contractile proteins of the cardiac sarcomere 2,
4. Typical morphological changes include myocyte hypertrophy
and disarray surrounding areas of increased loose connective
tissue. It is associated with arrhythmias and premature sudden
See Examples of different diseases that cause cardiomyopathies
Pointers in Examination:
- It is important to take a family history with specific enquiry about; deaths attributed to heart problems, sudden unexplained deaths, current symptoms in relatives that might suggest significant HCM.
- Try to obtain the death certificate/post-mortem report/ copy of ECHO's etc to verify diagnosis in an affected family member.
- The absence of a family history does not exclude this as a possible diagnosis. This can be a new mutation, or, a parent can carry a mutation and be asymptomatic.
- Refer to cardiologist for specific investigation / work up which is likely to include ; Echo, ECG, MRI, Holter and exercise test.
- Genetic testing for Familial HCM is available but expensive as there are many genes. This is not a first tier test but DNA can be stored in case testing is undertaken at a later date.
- If the cause of Familial HCM is not found in the proband, consider inpatient Genetics referral or refer case to the Cardiac Inherited Disease Group for discussion. Further family screening may be indicated in first degree relatives and further genetic testing may be warranted.
Restrictive cardiomyopathy is characterised by restrictive
diastolic filling and reduced diastolic volume in either or both
ventricles with normal or near-normal systolic function due to
excessively stiff ventricular walls often caused by infiltrative
disease processes 4. The ventricle remains normal in
size and maintains normal contractility, but the atria are enlarged
and out of proportion to the ventricles. The exact prevalence is
unknown but it is probably the least common type of cardiomyopathy
1. RCM can be difficult to define because restrictive
ventricular physiology occurs in a wide range of different
pathologies, it may be idiopathic, familial (Familial RCM mostly
characterized by autosomal dominant inheritance) or result from
other systemic disorders (i.e. amyloidosis, sarcoidosis,
anthracycline toxicity) 4.
Pointers in Examination:
- Take a family history
- Look for signs of a skeletal myopathy
- Consider referral to Clinical Genetics as part of the investigation of cause.
Features suggesting Metabolic Cardiomyopathies
- Metabolic cardiomyopathies are most frequently hypertrophic but dilatation can accompany hypertrophy and can be the predominant finding
- Metabolic cardiomyopathies can be accompanied by multi-system disease and a child should be investigated for this. For example; hypotonia may suggest infantile Pompe disease, rhabdomyolysis or hypoglycaemia may suggest a fatty acid oxidation disorder (FAOD), neutropenia suggests Barth syndrome and concomitant diabetes, deafness, eye, liver, renal or brain disease may suggest a mitochondrial respiratory chain defect.
- Infantile Pompe disease (IPD) is a rare but important genetic cause for HCM. It should be considered in all children with HCM, particularly if there is associated faltering growth, hypotonia or respiratory failure. Alglucosidase alfa (Myozyme®) is a recombinant, intravenous enzyme replacement therapy that is now funded by PHARMAC for use in IPD in New Zealand. The effectiveness of treatment is greatly influenced by age at diagnosis thus if IPD is suspected, the metabolic service should be notified for urgent review and initiation of testing.
- Neonatal cardiomyopathy associated with arrhythmia + hypoglycaemia is highly suggestive of a metabolic cause such as a long chain fatty acid oxidation defect. Rapid intervention with IV glucose can be life-saving and the metabolic consultant on call should be contacted immediately.
- Mode of inheritance is generally autosomal recessive however an X-linked pattern may suggest Hunter syndrome, Barth syndrome or Fabry disease, and maternal inheritance may suggest mitochondrial DNA related disease.
- Dysmorphic features might suggest a lysosomal storage disease (coarse facies, dysostosis, corneal clouding) peroxisomal biogenesis disorder or congenital disorders of glycosylation (CDG) (inverted nipples, fat pads).
- Unusual diets, prolonged TPN with time off lipids and therefore vitamins, may suggest a nutritional deficiency
- See Examples of different diseases that cause cardiomyopathies
Pointers in history / examination:
- A three generation family pedigree should be taken.
- A family history with specific enquiry about multi-system disease including; cardiac, renal, sensorineural hearing loss, recurrent miscarriages or early onset diabetes.
Checklist for acute presentation of DCM, HCM, RCM or acute myocarditis
Please Note: suggested investigations should be used as guide only and should not supersede clinical judgement
- Laboratory investigations taken on admission. See Investigations for acute presentation of DCM, HCM, RCM or acute myocarditis. Ensure all tests identified by * asterisk are taken prior to child receiving transfusion or immunoglobulin
- History: detailed history of presenting complaint, past history, developmental history.
- Full examination: looking for multisystem disease or dysmorphic features.
- Routine tests: minimum of CXR, ECG,
Consider Holter monitor and ophthalmology review
- Family Screening:
- Detailed history (at least 3 generation pedigree should be drawn); history of sudden unexplained death in young people / family history of cardiomyopathy / multisystem disease.
- Investigations; at least ECG and echocardiogram of parents and siblings
- Further family screening may be indicated in first degree relatives and metabolic and genetic testing may be warranted. See referrals below.
- If first tier investigations do not reveal cause, seek advice from cardiology, metabolic and genetic services and CIDG ( via operator).
- If there are features of a metabolic cardiomyopathy, in particular a FAOD or IPD, an urgent metabolic referral should be made.
- When requesting specific laboratory tests ensure you indicate your name and contact details clearly on the request form and the name of the consultant involved.
- Refer case to CIDG unless a positive diagnosis of a non-familial cause has been made e.g. myocarditis. Please also inform CIDG when testing has identified a non-familial cause. Contact firstname.lastname@example.org. or phone 23634 and ask for the coordinator. NB CIDG will NOT chase up all the results, but will obtain consent from the family for DNA storage and testing and record family details.
- Consider biopsy - skin, skeletal muscle, + liver and myocardium. See Muscle and Skin Biopsy Guideline for details of how to take these samples. Cardiac biopsy indicated: ensure metabolic team involved. PCR for candidate viruses (listed on Table 1).
- If infant / child deteriorating or for palliative
Discuss with relevant consultants the appropriate tests and storage / handling of samples as soon as practicable
Discuss with the Metabolic consultant to ensure appropriate tests are arranged (see Muscle and Skin Biopsy Guideline for correct storage and labeling).
Consider doing the following tests:
- Genetic testing: 1-2 ml minimum of EDTA blood - send to the molecular genetics lab for DNA extraction and storage.
- Take a skin biopsy for fibroblast culture in all patients within 12 hours of death
- Consider a muscle and/or liver biopsy, preferably pre or if not immediately after death, if mitochondrial or glycogen storage disease has been considered
- Discuss autopsy with family
- Investigations for acute presentation of DCM, HCM, RCM or acute myocarditis
Click on the image below to view a printable pdf of Investigations for acute presentation of DCM, HCM, RCM or acute myocarditis.
Examples of different diseases that cause cardiomyopathies
Click on the image below to view a printable pdf of this document
- Elliot, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F.,Charron, P., Dubourg, O., Kuhl,U., Maisch. B., McKenna, W., Monserrat, L., Pankuweit, S., Rapezzi, C., Seferovic, P., Tavazzi, L and Keren , A. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. European Heart Journal (2008) 29, 270-276.
- Maron, B., Chair; Towbin, J, Gaetano Thiene, G., Antzelevitch, G., Corrado, D., Arnett, D., Moss, A., Seidman, C., Young, J. Contemporary Definitions and Classification of the Cardiomyopathies : An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation (2006), 113:1807-1816.
- Colan, S. Classification of Cardiomyopathies. Progress in Pediatric cardiology , 23 (2007) 5-15
- Richardson, McKenna, W., Bristow, M., Maisch, B., Mautner, B., O'Connell, J., Olsen, E., Thiene, G., Goodwin, J., Gyarfas, IMartin, I., Nordet, P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation (1996) , 93(5):841-2]
- Gaetano Thiene, G., Corrado, D., Basso, C. Revisiting definition and classification of cardiomyopathies in the era of molecular medicine. European Heart Journal (2008) 29, 144-146
- Gajarski R and Towbin J. Recent advances in the etiology, diagnosis and treatment of myocarditis and cardiomyopathies in children. Current Opinion in Pediatrics. 1995; 7:587-594
- Mason JW. Classification of cardiomyopathies. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's the Heart, Arteries and Veins. 10th ed. New York, NY: McGraw Hill; 2001: 1941-1946.
- Park, M. The Pediatric cardiology hand book 3rd ed. Mosby , Inc., Philadelphia, U.S.A; 2003.
Did you find this information helpful?
- Date last published: 01 August 2013
- Document type: Clinical Guideline
- Services responsible: Metabolic, Paediatric Cardiology
- Author(s): Emma Glamuzina, John Stirling, Marion Hamer
- Editor: Greg Williams
- Review frequency: 2 years
SIGN UP TO RECEIVE GUIDELINE UPDATES
Subscribe below if you want us to let you know about new or updated guidelines
More From Starship
CareConnect TestSafe is a way for clinicians to get remote access to Starship clinical documents. Find out more...
Read about the governance process around the Starship Clinical Guidelines and how to format guidelines in development.